Parkinson's Drug Reduces Disease Markers in Breakthrough Trial

Produced by the US biotechnology company Vaxxinity, the immunotherapy candidate codenamed UB-312 is the first treatment shown to be capable of reducing concentrations ofThough the results of the trial are yet to be published and peer reviewed, reports from company officials are optimistic, suggesting they're onto something big.

In this latest randomized, double-blind trial on 20 patients diagnosed with Parkinson's disease, the antibodies were shown to bind exclusively to aggregated forms of α-syn. Analysis of the spinal fluid of those given UB-312 revealed a 20 percent drop in their usual α-syn aggregate levels, compared with a 3 percent decline in those who received a

"Currently, there are no treatments that address the underlying conditions of Parkinson's, and we are very excited about this target engagement data,""This provides us confidence that we are going after the right target and in a way that is statistically and clinically relevant to patients. There is new hope on the horizon."

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Taking on Parkinson’s Disease—With Boxing Gloves and Punching BagsIn a California gym, people living with Parkinson’s practice boxing to redefine their experience of the disease and maintain a sense of self.
Source: SAPIENS_org - 🏆 227. / 63 Read more »

Remarkable new treatment helps people with tremors like those linked to Parkinson’s diseaseHCA Florida Orange Park is now the first hospital in our area to offer this option to patients with tremor-predominant Parkinson's disease and essential tremors.
Source: wjxt4 - 🏆 246. / 63 Read more »

New Parkinson's drug Produodopa to be available on NHSThe treatment will mean many people no longer needing to take more than 20 pills across the day.
Source: bbchealth - 🏆 143. / 63 Read more »

Early drug treatment leads to better outcomes for Crohn’s diseaseAbout 80 per cent of people who received infliximab straight after diagnosis with the inflammatory bowel condition had controlled their symptoms after a year, compared with just 15 per cent of those following a standard regime
Source: newscientist - 🏆 541. / 51 Read more »

FDA approves weight-loss drug Wegovy to reduce heart-disease risksThe FDA approved the weight-loss drug Wegovy as a treatment to reduce cardiovascular risk in adults who are overweight, the first approval of its kind.
Source: washingtonpost - 🏆 95. / 72 Read more »

Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drugWegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.
Source: FoxBusiness - 🏆 458. / 53 Read more »